The Efficacy and Safety of OM-89 in Patients With Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Phase 4 Unknown 332 enrolled AJU Pharm Co., Ltd. OM Pharma SA · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is planned to Evaluate the Efficacy and Safety of OM-89 in Patients with Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)

Timeline

Start: 2023-12-20
Primary completion: 2025-12-30
Completion: 2026-03-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	OM-89	Other / unclassified	6 mg	Oral

The Efficacy and Safety of OM-89 in Patients With Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Summary

Timeline

Drugs

Indications